TSHA - Taysha Gene Therapies  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TSHA is currently covered by 8 analysts with an average price target of $10.54. This is a potential upside of $8.22 (354.31%) from yesterday's end of day stock price of $2.32.

Taysha Gene Therapies 's activity chart (see below) currently has 38 price targets and 90 ratings on display. The stock rating distribution of TSHA is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 18.58% with an average time for these price targets to be met of 84.31 days.

Highest price target for TSHA is $8, Lowest price target is $5, average price target is $6.63.

Most recent stock forecast was given by SILVAN TUERKCAN from JMP on 27-Apr-2025. First documented stock forecast 18-Oct-2020.

Currently out of the existing stock ratings of TSHA, 42 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$5

$2.87 (134.74%)

$5

15 days ago
(27-Apr-2025)

2/9 (22.22%)

$3.2 (177.78%)

401

Buy

$7

$4.87 (228.64%)

$7

15 days ago
(27-Apr-2025)

1/12 (8.33%)

$5.2 (288.89%)

137

Buy

$6

$3.87 (181.69%)

$6

1 months 3 days ago
(09-Apr-2025)

0/18 (0%)

$4.83 (412.82%)

Buy

$8

$5.87 (275.59%)

$6

5 months 28 days ago
(14-Nov-2024)

0/4 (0%)

$5.94 (288.35%)

Buy

$7

$4.87 (228.64%)

$7

10 months 25 days ago
(17-Jun-2024)

0/6 (0%)

$4.03 (135.69%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TSHA (Taysha Gene Therapies ) average time for price targets to be met?

On average it took 84.31 days on average for the stock forecasts to be realized with a an average price target met ratio 18.58

Which analyst has the current highest performing score on TSHA (Taysha Gene Therapies ) with a proven track record?

SALVEEN RICHTER

Which analyst has the most public recommendations on TSHA (Taysha Gene Therapies )?

Salveen Richter works at GOLDMAN SACHS and has 8 price targets and 5 ratings on TSHA

Which analyst is the currently most bullish on TSHA (Taysha Gene Therapies )?

Yanan Zhu with highest potential upside - $8.37

Which analyst is the currently most reserved on TSHA (Taysha Gene Therapies )?

Gbola Amusa with lowest potential downside - -$0

Taysha Gene Therapies  in the News

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

DALLAS, May 08, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, May 02, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2025, the Compensation Committee of Taysha’s Board of Directors granted...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?